Subscribe
29 August 2017Asia

AstraZeneca and Takeda enter agreement to develop Parkinson’s disease drug

AstraZeneca and Takeda have entered into an agreement to develop and commercialise MEDI1341, an alpha-synuclein antibody currently in development as a potential treatment for Parkinson’s disease (PD).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Generics
Class-action accuses Takeda of ‘pay-for-delay’ deal with Par
1 July 2021   Takeda Pharmaceuticals organised a pay-for-delay deal with Par Pharmaceuticals to prevent a generic version of its constipation treatment from releasing, according to a complaint submitted to the US District Court for the District of Massachusetts.
Generics
Takeda faces ‘pay-for-delay’ class-action suit over anti-constipation drug
5 August 2021   Takeda Pharmaceuticals is the target of a proposed class action that alleges the pharma giant paid to keep a generic anti-constipation drug off the market.
Generics
Second Circuit says Takeda can’t dodge two antitrust suits
26 August 2021   The US Court of Appeals for the Second Circuit has denied an appeal from Takeda Pharmaceuticals to shut down two antitrust suits related to its diabetes drug Actos.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Generics
Class-action accuses Takeda of ‘pay-for-delay’ deal with Par
1 July 2021   Takeda Pharmaceuticals organised a pay-for-delay deal with Par Pharmaceuticals to prevent a generic version of its constipation treatment from releasing, according to a complaint submitted to the US District Court for the District of Massachusetts.
Generics
Takeda faces ‘pay-for-delay’ class-action suit over anti-constipation drug
5 August 2021   Takeda Pharmaceuticals is the target of a proposed class action that alleges the pharma giant paid to keep a generic anti-constipation drug off the market.
Generics
Second Circuit says Takeda can’t dodge two antitrust suits
26 August 2021   The US Court of Appeals for the Second Circuit has denied an appeal from Takeda Pharmaceuticals to shut down two antitrust suits related to its diabetes drug Actos.

More on this story

Generics
Class-action accuses Takeda of ‘pay-for-delay’ deal with Par
1 July 2021   Takeda Pharmaceuticals organised a pay-for-delay deal with Par Pharmaceuticals to prevent a generic version of its constipation treatment from releasing, according to a complaint submitted to the US District Court for the District of Massachusetts.
Generics
Takeda faces ‘pay-for-delay’ class-action suit over anti-constipation drug
5 August 2021   Takeda Pharmaceuticals is the target of a proposed class action that alleges the pharma giant paid to keep a generic anti-constipation drug off the market.
Generics
Second Circuit says Takeda can’t dodge two antitrust suits
26 August 2021   The US Court of Appeals for the Second Circuit has denied an appeal from Takeda Pharmaceuticals to shut down two antitrust suits related to its diabetes drug Actos.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Attorney v examiner: Navigating patenting's AI tools ‘arms race’
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool